GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype
Alzheimer's Prevention Registry GeneMatch Program
1 other identifier
observational
500,000
1 country
1
Brief Summary
The purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large group of people interested in participating in research studies or clinical trials based in part on their genetic background. This genetic information will be used to match interested individuals to studies, providing a recruitment resource to the Alzheimer's scientific community. Interested individuals should visit www.endALZnow.org/GeneMatch to join the GeneMatch program.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2015
CompletedFirst Posted
Study publicly available on registry
October 1, 2015
CompletedStudy Start
First participant enrolled
November 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
December 9, 2025
December 1, 2025
15.1 years
September 29, 2015
December 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of individuals who enroll in GeneMatch
15 years
Secondary Outcomes (2)
Number of individuals referred to research studies
15 years
Number of individuals who enroll in research studies
15 years
Eligibility Criteria
This large research study will ultimately enroll 500,000 adults. We will recruit subjects from all over the United States, as everything is done via email, mail, or/and phone.
You may qualify if:
- Age 50-90, inclusive
- Provide basic demographic, medical history, and contact information
- Consent to APOE genotyping without receiving results
- Live in the United States
You may not qualify if:
- Unable to comply with this project's protocol requirements
- Self-reported diagnosis of dementia or any other objective cognitive impairment syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Banner Healthlead
Study Sites (1)
Banner Alzheimer's Institute
Phoenix, Arizona, 85006, United States
Related Publications (2)
Langbaum JB, Karlawish J, Roberts JS, Wood EM, Bradbury A, High N, Walsh TL, Gordon D, Aggarwal R, Davis P, Stowell C, Trisko L, Langlois CM, Reiman EM, Tariot PN. GeneMatch: A novel recruitment registry using at-home APOE genotyping to enhance referrals to Alzheimer's prevention studies. Alzheimers Dement. 2019 Apr;15(4):515-524. doi: 10.1016/j.jalz.2018.12.007. Epub 2019 Feb 13.
PMID: 30772251RESULTStites SD, Dedhia M, Harkins K, Karlawish J, Langbaum JB, Mather M, Barber SJ. Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma. Psychol Aging. 2026 Feb 23. doi: 10.1037/pag0000970. Online ahead of print.
PMID: 41729767DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jessica B Langbaum, PhD
Banner Alzheimer's Institute
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 15 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Director, Research Strategy
Study Record Dates
First Submitted
September 29, 2015
First Posted
October 1, 2015
Study Start
November 1, 2015
Primary Completion (Estimated)
December 1, 2030
Study Completion (Estimated)
December 1, 2030
Last Updated
December 9, 2025
Record last verified: 2025-12